Prometheus Biosciences Inc Stock News

The clinical-stage biotech that specializes in IBD therapies announced positive news regarding two trials for its lead therapy.

At least two biotech stocks are triggering an options trading frenzy today, with Prometheus Biosciences Inc (NASDAQ:RXDX) and Esperion Therapeutics Inc (NASDAQ:ESPR) moving in opposite directions

Prometheus Biosciences Inc shares have rocketed more than 170% on positive results for its therapeutic candidate PRA023 in both its ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. Prometheus is dev

Prometheus Biosciences (NASDAQ: RXDX ) stock is rocketing higher on Wednesday after reporting results from its ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies of PRA023. PRA023 is a treatment in dev

Prometheus Bio reported promising results from two inflammatory disease studies on Wednesday, and RXDX stock catapulted higher. The post Prometheus Biosciences Catapults 176% On Promising Results In I

Shares of Prometheus Biosciences Inc. RXDX, -4.40% soared 177.0% in premarket trading on Wednesday after the company said it will advance an experimental therapy into Phase 3 clinical trials for ulcer

The company's lead pipeline candidate is facing competition from a Pfizer-backed drug.

Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of -1.12% and 26.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for

Mid-cap companies are those that fall between small and large cap companies. Thus, they are more stable than small-cap companies and, at the same time, offer higher growth opportunities than large-cap

A little-known biotech chasing Pfizer's tail could soon skyrocket.

A new White House program will likely boost the entire biotech industry. And it makes these seven names some outstanding biotech stocks to buy for the fourth quarter.

Prometheus Biosciences, Inc. (RXDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of 6.52% and 81.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the st

Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of -5.13% and 459.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the

- Topline results for ongoing Phase 2 clinical trial in ulcerative colitis and Phase 2a trial in Crohn’s disease expected in fourth quarter 2022 -